Jhala NC - Search Results

1

Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis.

Jing G, Yuan K, Turk AN, Jhala NC, Arnoletti JP, Zhang K, McDonald JM, Chen Y. Jing G, et al. Among authors: jhala nc. Lab Invest. 2011 Jun;91(6):896-904. doi: 10.1038/labinvest.2011.60. Epub 2011 Apr 4. Lab Invest. 2011. PMID: 21464824 Free article.

2

Regulators of apoptosis in cholangiocarcinoma.

Jhala NC, Vickers SM, Argani P, McDonald JM. Jhala NC, et al. Arch Pathol Lab Med. 2005 Apr;129(4):481-6. doi: 10.5858/2005-129-481-ROAIC. Arch Pathol Lab Med. 2005. PMID: 15794670 Free article.

3

Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin.

Pawar P, Ma L, Byon CH, Liu H, Ahn EY, Jhala N, Arnoletti JP, McDonald JM, Chen Y. Pawar P, et al. Clin Cancer Res. 2009 Feb 15;15(4):1288-96. doi: 10.1158/1078-0432.CCR-08-1150. Clin Cancer Res. 2009. PMID: 19228732 Free PMC article.

4

Fas-mediated apoptosis in cholangiocarcinoma cells is enhanced by 3,3'-diindolylmethane through inhibition of AKT signaling and FLICE-like inhibitory protein.

Chen Y, Xu J, Jhala N, Pawar P, Zhu ZB, Ma L, Byon CH, McDonald JM. Chen Y, et al. Am J Pathol. 2006 Nov;169(5):1833-42. doi: 10.2353/ajpath.2006.060234. Am J Pathol. 2006. PMID: 17071604 Free PMC article.

5

Reciprocal co-expression of Fas and Fas ligand in human cholangiocarcinoma.

Pan G, Ahn EY, Chen Y, Feng G, Reddy V, Jhala NC, McDonald JM. Pan G, et al. Among authors: jhala nc. Int J Oncol. 2007 Oct;31(4):843-50. Int J Oncol. 2007. PMID: 17786316

6

Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma).

Vickers SM, Jhala NC, Ahn EY, McDonald JM, Pan G, Bland KI. Vickers SM, et al. Among authors: jhala nc. Ann Surg. 2002 Jun;235(6):872-8. doi: 10.1097/00000658-200206000-00016. Ann Surg. 2002. PMID: 12035045 Free PMC article.

7

Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.

Xu F, Sun Y, Yang SZ, Zhou T, Jhala N, McDonald J, Chen Y. Xu F, et al. Int J Cancer. 2019 Jul 15;145(2):474-483. doi: 10.1002/ijc.32108. Epub 2019 Jan 24. Int J Cancer. 2019. PMID: 30614530 Free PMC article.

8

A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.

Arnoletti JP, Frolov A, Eloubeidi M, Keene K, Posey J, Wood T, Greeno E, Jhala N, Varadarajulu S, Russo S, Christein J, Oster R, Buchsbaum DJ, Vickers SM. Arnoletti JP, et al. Cancer Chemother Pharmacol. 2011 Apr;67(4):891-7. doi: 10.1007/s00280-010-1383-0. Epub 2010 Jun 30. Cancer Chemother Pharmacol. 2011. PMID: 20589377 Free PMC article. Clinical Trial.

9

Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer.

Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ, Arnoletti JP. Tzeng CW, et al. Among authors: jhala nc. Surgery. 2007 Apr;141(4):464-9. doi: 10.1016/j.surg.2006.09.009. Epub 2007 Jan 22. Surgery. 2007. PMID: 17383523

10

Pancreatic cancer epidermal growth factor receptor (EGFR) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.

Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Vickers SM, Buchsbaum DJ, Heslin MJ, Arnoletti JP. Tzeng CW, et al. Among authors: jhala nc. Ann Surg Oncol. 2007 Jul;14(7):2150-8. doi: 10.1245/s10434-007-9409-5. Epub 2007 Apr 24. Ann Surg Oncol. 2007. PMID: 17453292

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

161 results

Search Page

Filters